Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference
Clearside Biomedical announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12, 2022.
Clearside’s presentation, entitled “The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians,” described the preclinical and clinical data demonstrating the methodology and benefits of suprachoroidal delivery. The preclinical data in multiple animal models showed the potential advantages of SCS delivery over intravitreal delivery, the durability potential of small molecule suspensions, and the possible suitability of suprachoroidal delivery for gene therapy. In conjunction with partners, Clearside’s technology is currently being explored in five clinical trials in four indications: neovascular age-related macular degeneration (wet AMD), diabetic retinopathy, uveitic macular edema, and choroidal melanoma.
“Suprachoroidal delivery via our SCS Microinjector offers clinicians several potential core benefits for treatment of their patients with back of the eye diseases: targeting of therapy to affected tissues; compartmentalization of therapy to avoid non-diseased tissues; higher bioavailability; and potential longer durability,” Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, said in a company news release. “As presented last weekend, our SCS injection platform can be utilized with a variety of therapies, including small molecules and gene therapy. We are proud to be the pioneers in treating serious retinal diseases through the innovative and noninvasive suprachoroidal delivery approach.”
In addition, Clearside’s partner, Regenxbio, presented additional positive interim data from its phase 2 clinical trial, entitled ALTITUDE, of RGX-314 for the treatment of diabetic retinopathy without center-involved diabetic macular edema delivered suprachoroidally using the SCS Microinjector. RGX-314 is being investigated as a potential one-time gene therapy for the treatment of wet AMD and diabetic retinopathy. In the trial, RGX-314 continues to be well tolerated at 6 months following a one-time, in-office suprachoroidal injection, with nearly 50 percent of patients dosed with RGX-314 in Cohort 1 demonstrating a clinically meaningful improvement from baseline, compared to 0% of patients in observational control, with no drug-related serious adverse events at six months and no intraocular inflammation observed.